Biotechnology

LAKESHORE BIOPHARMA CO LTD

Lakeshore Biopharma Co Ltd released FY2025 earnings on July 31 (EST), actual revenue USD 85.29 M (forecast USD 109.25 M), actual EPS USD -0.7237

Lakeshore Biopharma Co Ltd released FY2024 earnings on July 31 (EST), actual revenue USD 79.41 M (forecast USD 82.56 M), actual EPS USD -5.6139

Lakeshore Biopharma Co Ltd released FY2023 Annual Earnings on July 31, 2025 (EST), Actual Revenue: USD 99.49 M, Actual EPS: USD -3.4088

Energy Focus

Forum Markets

Tradr 2X Long CRML Daily ETF

Leverage Shares 2X Long CRML Daily ETF

Kailera Therapeutics

Beasley Broadcast

CO2 ENERGY TRANSITION CORP. COM USD0.0001 15/10/2028 (SUB/RIGHTS)

Blaize

Fold

Critical Metals

Kiniksa Pharmaceuticals

Rigel Pharma

MiMedx

CapForce Inc.

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

LAKESHORE BIOPHARMA CO LTD(LSBCF.US)

LAKESHORE BIOPHARMA CO LTD Stock Performance Chart